MAY 0 1 2002
PATENT & TRADEMARK OFFICE
JC26 Rec'd PCT/PTO

RECEIVED
MAY 0 3 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	09/986,234
				Filing Date	October 22, 2001
				First Named Inventor	Lazar
(use as many sheets as necessary)				**Group Art Unit**	~~1645~~ 1644
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	**Attorney Docket Number**	053893-5032-01

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	5,023,243		Tullis	06-11-1991
	5,498,531		Jarrell	03-12-1996

FOREIGN PATENT DOCUMENTS						
Exr Initials	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T_1
	Country Code	Number	Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T_1
	Berger et al., 1996, Endocrinology 137:4189-4195	
	Burris et al., 1999, Mol. Endocrinol. 13:410-417	
	Cohen et al., 1996, Adv. Chromatogr. 36:127-162	
	Fujita et al., 1983, Diabetes 32:804-810	
	Fujiwara et al., 1988, Diabetes 37:1549-1558	
	Henry, 1997, Endo. Metab. Clin. North Amer. 26:553-573	
	Hiragun et al., 1988, J. Cell. Physiol. 134:124-130	
	Inzucchi et al., 1998, N. Engl. J. Med. 338:867-869	
	Kawamatsu et al., 1980, Arznein.-Forsch./Drug Res. 30:454-459	
	Kletzien et al., 1992, Mol. Pharmacol. 41:393-398	
	Kumar et al., 1996, Diabetologia 39:701-709	
	Larkins, 1997, TEM 8:187-191	
	Lemberger et al., 1996, Annu. Rev. Cell Dev. Biol. 12:335-363	
	Lukkarinen et al., 1997, Stroke 28:639-645	
	Olefsky, 1985, Am. J. Med. 79:1-7	
	Reaven, 1993, Ann. Rev. Med. 44:121-131	
	Schwartz et al., 1998, N. Engl. J. Med. 338:861-866	
	Spencer and Markham, 1997, Drugs 54:89-101	
	Suter et al., 1992, Diabetes Care 15:193-203	
	Watkins and Whitcomb, 1998, N. Engl. J. Med. 338:916-917	
	Wianny and Zernicka-Goetz, 2000, Nature Cell Biol. 2:70-75	
	Wilson et al., 1996, J. Med. Chem. 39:665-668	

Examiner Signature	7/31/06	Date Considered	

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	09/986,234
				Filing Date	October 22, 2001
				First Named Inventor	Mitchell A. Lazar et al.
(use as many sheets as necessary)				**Group Art Unit**	~~1632~~ 1644
				Examiner Name	Anne-Marie Falk, Ph.D.
Sheet	1	of	1	**Attorney Docket Number**	053893-5032-01

OIPE JC46 JUL 16 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS						
Exr Initials	Foreign Patent Document Country Code	Number	Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T_1
		WO 98/58061		Schering Corporation	12-23-1998	
		WO 99/11293		Human Genome Sciences, Inc.	03-11-1999	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T_1

Examiner Signature	1-PH/2051909.1	7/31/05	Date Considered	

OIPE JC10
FEB 22 2006
PATENT & TRADEMARK OFFICE

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/986,234
Filing Date	October 22, 2001
First Named Inventor	M. Lazar
Group Art Unit	1632
Examiner Name	A. Falk
Attorney Docket Number	UPN-L2066AUSA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2](if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2001-0011077	08-02-2001	Albone et al.	
	AB	2002-0111476	08-15-2002	Franz-Bacon et al.	
	AC	2003-0166906	09-04-2003	Moore et al.	
	AD	2004-0018980	01-29-2004	Gurney et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]- Number[4]-Kind Code[5](if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AL	WO-00/00610	01-06-2000	Lal et al.		
	AM	WO-00/04923	02-03-2000	Albone et al.		
	AN	WO-00/05259	02-03-2000	Albone et al.		
	AO	WO-00/20447	04-13-2000	Shimkets		
	AP	WO-99/31236	06-24-1999	Bougueleret et al.		
	AQ	WO-99/55868	11-04-1999	Gurney et al.		

Examiner Signature	7/31/06	Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OIPE JC10 FEB 22 2005 PATENT & TRADEMARK OFFICE

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/986,234
Filing Date	October 22, 2001
First Named Inventor	M. Lazar
Group Art Unit	~~1632~~ 1644
Examiner Name	A. Falk
Attorney Docket Number	UPN-L2066AUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	AR	FORMAN et al., "Unique response pathways are established by allosteric interactions among nuclear hormone receptors", *Cell* **May 19, 1995** 81(4):541-550	
	AS	FRIEDMANN, T., "Overcoming the obstacles to gene therapy", *Sci. Amer.* **June 1997** 276(6):96-101	
	AT	HOLCOMB et al., "FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family", *EMBO J.* **August 1, 2000** 19(15):4046-4055	
	AU	KLIEWER et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma", *Proc. Nat. Acad. Sci. USA* **April 29, 1997** 94(9):4318-4323	
	AV	MUKHERJEE et al., "Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists", *Nature* **May 27, 1999** 386(6623):407-410	
	AW	ORKIN et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy", **December 7, 1995**	
	AX	REGINATO et al., "Mechanisms by which Thiazolidinediones Enhance Insulin Action", *Trends Endo. Metab.* **December 1999** 10(1):9-13	
	AY	STEPPAN et al., "A family of tissue-specific resistin-like molecules", *Proc. Nat. Acad. Sci. USA* **January 16, 2001** 98(2):502-506	
	AZ	STEPPAN et al., "Resistin and obesity-associated insulin resistance", *Trends Endo. Metab.* **January-February 2002** 13(1):18-23	
	BR	STEPPAN et al., "The hormone resistin links obesity to diabetes", *Nature* **January 18, 2001** 409(6818):307-312	

Examiner Signature		Date Considered	7/31/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OIPE JC10
FEB 22 2005
PATENT & TRADEMARK OFFICE

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

	Complete if Known
Application Number	09/986,234
Filing Date	October 22, 2001
First Named Inventor	M. Lazar
Group Art Unit	~~1632~~ 1644
Examiner Name	A. Falk
Attorney Docket Number	UPN-L2066AUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	BS	TONTONOZ et al., "Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor", *Cell* **December 30, 1994** 79(7):1147-1156	
	BT	VERMA et al., "Gene therapy -- promises, problems and prospects", *Nature* **September 18, 1997** 389(6648):239-242	
	BU	WALL, R.J., "Transgenic livestock: Progress and prospects for the future", *Theriogenology* **January 1, 1996** 45(1):57-68	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.